IRWD
IronwoodANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
LINZESS remains the core cash engine, Q1 showed very strong U.S. net-sales growth, the new pediatric FC approval expands the label, and apraglutide still offers a longer-duration second catalyst if the Phase 3 path stays on track.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +10.3.
What can break
Apraglutide remains earlier-stage and still carries development, regulatory, and timing risk.
Momentum
39
Value
70
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.40 · Bull $8.00 · Bear $2.40
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $7.88
Why
Momentum39 · Δ7d -24.2
Value70 · Δ7d +0.7
Sentiment100 · Δ7d +10.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
39
34% active weight
Current posture
7d trendSoftening
Δ7d
-24.2
Δ21d
-48.2
Value
70
32% active weight
Current posture
7d trendFlat
Δ7d
+0.7
Δ21d
+1.1
Sentiment
100
33% active weight
Current posture
7d trendImproving
Δ7d
+10.3
Δ21d
+40.7
Why this grade
Composite grade A. Momentum 38.9 / Value 69.7 / Sentiment 100.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$569.56M
Beta
0.16
Shares Out
162.68M
P/E (TTM)
32.7
P/S (TTM)
2.20
P/FCF (TTM)
11.04
Rev YoY
+33.3%
EPS YoY
+891.1%
Gross Margin
-
Op Margin
+36.3%
Net Debt
$495.43M
Current Ratio
1.13
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology